Business Wire

CA-JUNIPER-NETWORKS

18.7.2024 09:31:26 CEST | Business Wire | Press release

Share
Telxius Upgrades Its Global Network to 400G With a Converged Optical Routing Architecture by Juniper Networks

Telxius, a leading global connectivity provider, is scaling its core and edge network infrastructure to 400G with a Converged Optical Routing Architecture (CORA) provided by Juniper Networks (NYSE:JNPR), a leader in secure AI-Native Networks. This will enable a simplified network capacity expansion and efficient delivery of enhanced connectivity to metro networks and data center interconnects (DCI). It provides connectivity across distances of around 100 km to points of presence (PoPs) across Telxius’ global footprint in Spain, the Americas, and wider Europe.

Telxius connects millions of customers globally, providing a wide range of capacity, colocation and security services, as well as direct internet connectivity through its Tier-1 IP network. Its extensive ecosystem combines fiber optic submarine cables and terrestrial backhauls together spanning 100,000+ km, almost 100 PoPs in 17 countries, plus 27 data centers. Telxius seamlessly connects customers with ultra-high capacity, low latency and resilient networking.

Telxius will migrate some of its key architecture to Juniper’s CORA and PTX Series Packet Transport Routers to deliver a network that offers robust power and space savings superior performance and automated operations. This will free up a substantial amount of reserved bandwidth and allow for flexible extension to 400G capacity. The project will create enhanced connectivity for Telxius’ customers and create a more sustainable architecture by optimizing network scalability and bandwidth efficiency.

The solution leverages leading edge technology with the use of an IP over Dense Wavelength Division Multiplexing (IPoDWDM) solution. This maximizes routing platform capacity, scales up link bandwidth, and can reach more network locations and customers whilst removing the need to manage and maintain external DWDM equipment.

Using Juniper’s CORA, Telxius will simplify the network architecture by consolidating previously siloed IP and optical network layers into a unified system leveraging IPoDWDM. Once the project is complete, Telxius expects to increase network reliability for its customers, simplify network operations and substantially reduce power consumption.

“This project is a fantastic step forward to bring added scalability and capacity to the Telxius network through 400G coherent pluggable optics, meeting our customers’ needs in today’s ever-growing digital economy. Telxius is at the forefront of innovation, ensuring reduced power consumption and a simplified network architecture to provide a better experience for our customers. We anticipate a number of vendor-agnostic solutions that could support this architecture, and we are excited to collaborate with Juniper to build a solid foundation for further network expansion, said Carlos Dasi, CTO, Telxius.

“400G optics are a highly reliable solution to further enhance Telxius’ infrastructure to enable the best experience for customers. Telxius is leading the way for network innovation with the deployment of Juniper’s PTX and CORA, and Juniper is proud to enable this network transformation. Juniper’s optics solutions provide a simplified integration with Juniper infrastructure that allows the customer to scale up and scale out their network in line with their business goals. Built to last, this network transformation will extend Telxius’ network longevity to future-proof the business,” said Julius Francis, Senior Director of Product Marketing, Juniper Networks.

About Telxius

As the world’s needs for uninterrupted global interconnectivity continue to rise, we are preparing the road ahead. Telxius is a leading global connectivity provider that combines subsea and terrestrial networks with data centers worldwide. Its extensive ecosystem includes eight next-generation fiber optic submarine cables and terrestrial backhauls together spanning 100,000+ km, almost 100 PoPs in 17 countries, plus 25 landing stations. Telxius provides a wide range of capacity, colocation and security services, as well as direct internet connectivity through its Tier-1 IP network. With ultra-high capacity, low latency and resilient networking, Telxius seamlessly connects customers across the Americas, Europe and beyond. For more information about Telxius visit www.telxius.com.

About Juniper Networks

Juniper Networks believes that connectivity is not the same as experiencing a great connection. Juniper's AI-Native Networking Platform is built from the ground up to leverage AI to deliver exceptional, highly secure and sustainable user experiences from the edge to the data center and cloud. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on X (Twitter), LinkedIn, and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240718748438/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye